CN107849151B - 融合多肽及使用方法 - Google Patents

融合多肽及使用方法 Download PDF

Info

Publication number
CN107849151B
CN107849151B CN201680041325.1A CN201680041325A CN107849151B CN 107849151 B CN107849151 B CN 107849151B CN 201680041325 A CN201680041325 A CN 201680041325A CN 107849151 B CN107849151 B CN 107849151B
Authority
CN
China
Prior art keywords
seq
arg
lys
fusion polypeptide
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680041325.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849151A (zh
Inventor
刘宏宇
赵明治
孙赫彤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosit Sole Biotechnology Beijing Co ltd
Original Assignee
Prosit Sole Biotechnology Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosit Sole Biotechnology Beijing Co ltd filed Critical Prosit Sole Biotechnology Beijing Co ltd
Publication of CN107849151A publication Critical patent/CN107849151A/zh
Application granted granted Critical
Publication of CN107849151B publication Critical patent/CN107849151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680041325.1A 2015-07-15 2016-07-15 融合多肽及使用方法 Active CN107849151B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/084133 2015-07-15
CNPCT/CN2015/084133 2015-07-15
PCT/CN2016/090110 WO2017008758A1 (en) 2015-07-15 2016-07-15 Fusion polypeptides and methods of use

Publications (2)

Publication Number Publication Date
CN107849151A CN107849151A (zh) 2018-03-27
CN107849151B true CN107849151B (zh) 2022-05-24

Family

ID=57756671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680041325.1A Active CN107849151B (zh) 2015-07-15 2016-07-15 融合多肽及使用方法

Country Status (5)

Country Link
US (2) US11020454B2 (enExample)
EP (2) EP3322736B1 (enExample)
JP (1) JP6951318B2 (enExample)
CN (1) CN107849151B (enExample)
WO (1) WO2017008758A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020454B2 (en) 2015-07-15 2021-06-01 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5728546A (en) * 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
PL192537B1 (pl) * 1996-10-16 2006-11-30 Zymogenetics Inc Izolowana cząsteczka polinukleotydu kodująca polipeptyd homologiczny z czynnikiem wzrostu fibroblastów (FGF), wektor ekspresji, hodowane komórki, sposób wytwarzania polipeptydu, izolowany polipeptyd, polipeptyd homologiczny, kompozycja farmaceutyczna, przeciwciało, zastosowanie polipeptydu, sposób stymulacji i zastosowanie cząsteczki zawierającej polipeptyd FGF sprzężonej z drugą cząsteczką
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US7470665B2 (en) * 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7414019B2 (en) * 2002-10-04 2008-08-19 Auckland Uniservices Limited FGF-8 methods of use
CA2592261C (en) * 2004-12-10 2015-11-24 Zymogenetics Inc. Fgf18 production in prokaryotic hosts
KR20080105096A (ko) 2006-02-28 2008-12-03 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 치근형성 촉진제 및 치근형성 촉진방법
AR062522A1 (es) * 2006-08-25 2008-11-12 Ares Trading Sa Tratamiento de desordenes en cartilagos
MY148277A (en) * 2006-08-25 2013-03-29 Ares Trading Sa Treatment of cartilage disorders with fgf-18
JP5004250B2 (ja) * 2007-10-12 2012-08-22 独立行政法人産業技術総合研究所 高機能化キメラ蛋白質を含有する医薬組成物
KR101952453B1 (ko) 2009-10-15 2019-02-26 제넨테크, 인크. 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
WO2012038953A2 (en) * 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
WO2013006486A2 (en) * 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2014004465A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US11020454B2 (en) 2015-07-15 2021-06-01 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use

Also Published As

Publication number Publication date
US20180200333A1 (en) 2018-07-19
US20210322516A1 (en) 2021-10-21
JP6951318B2 (ja) 2021-10-20
US11020454B2 (en) 2021-06-01
EP3322736A1 (en) 2018-05-23
CN107849151A (zh) 2018-03-27
WO2017008758A1 (en) 2017-01-19
EP3322736A4 (en) 2019-02-20
EP3957654A1 (en) 2022-02-23
JP2018524005A (ja) 2018-08-30
EP3322736B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
US10624957B2 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EA017690B1 (ru) Мутанты fgf21 и их применение
KR20120036947A (ko) 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
WO2020052570A1 (zh) 预防和治疗动脉粥样硬化及相关疾病的方法和组合物
US20210322516A1 (en) Fusion polypeptides and methods of use
JP2013535954A (ja) ペプチド、構造体およびその使用
US7402303B2 (en) Chemokine mutants in the treatment of multiple sclerosis
WO2021249555A1 (en) Fusion polypeptide
AU2002215919A1 (en) Chemokine mutants in the treatment of multiple sclerosis
JPH06220099A (ja) 可溶性ｌｄｌリセプター
CN102675422A (zh) 抗乙型肝炎病毒x蛋白多肽药物
KR101625112B1 (ko) 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
Knittel et al. Acidosis Increases MHC Class II–Restricted Presentation of a Protein Endowed with a pH-Dependent Heparan Sulfate–Binding Ability
WO2022093671A9 (en) Granulocyte macrophage-colony stimulating factor mutants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant